Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81
Document › Details

Expression Pathology Inc.. (1/11/11). "Press Release: Expression Pathology Provides Roche Its Liquid Tissue-SRM Protein Biomarker Assay Services in Drug Development". Rockville, MD.

Organisations Organisation Expression Pathology Inc. (EPI)
  Today OncoPlex Diagnostics (OncoPlexDx)
  Group OncoPlex Diagnostics (OncoPlexDx)
  Organisation 2 Roche (Group)
Products Product Liquid Tissue® technology (Expression Pathology)
  Product 2 mass spectrometry services (MS services)
Persons Person Eitner, Casey (Expression Pathology 200806 CEO)
  Person 2 Tunon, Peter (Expression Pathology 200501– VP Sales + Marketing)
     


Expression Pathology Inc. announced an agreement with Roche (SIX:RO, ROG; OTCQX:RHHBY) wherein Expression Pathology will provide its Liquid Tissue®-SRM Technology to accelerate identification of cancer molecular markers for developing more effective treatments.

Under the terms of the agreement, Expression Pathology will support Roche oncology drug development programs with multiplexed quantitative assays of cancer signaling pathway proteins and their activation in FFPE tissues by mass spectrometry.

“This new approach to tissue analysis has the potential to dramatically stream-line and improve biomarker identification in FFPE samples during clinical development,” says Dr. Miro Venturi, Senior Biomarker & Experimental Medicine Leader at Roche. “Longer-term, we may envision Expression Pathology’s Liquid Tissue®-SRM platform as becoming a new way of profiling tumors at the molecular level to improve patient stratification and therefore advancing our discovery of personalized medicines.”

“This collaboration with Roche is a key step towards developing valuable clinical assays to improve patient treatment decisions for Roche’s innovative new targeted therapies.” says Casey Eitner, President and CEO of Expression Pathology.


About Expression Pathology Inc.

Expression Pathology is advancing personalized medicine with assays that measure cancer signaling networks—at the functional protein level—in FFPE tissue to individualize and improve patient treatment decisions. Expression Pathology's patented Liquid Tissue®-SRM technology platform makes possible highly multiplexed protein quantitation by powerful mass spectrometry of minute amounts of laser microdissected FFPE tissue.

Expression Pathology offers a broad menu of multiplexed SRM assays for major cancer signaling networks to advance development of targeted therapies and improve patient stratification. The assays include a range of drug target pathway proteins including EFGR, IGF-1R, cMET, Her3, cSRC, MEK, and their phosphorylation states, as well as many others.

For more information contact:

Expression Pathology Inc.
Peter Tunon, Vice President Sales and Marketing
9620 Medical Center Drive, Suite 100
Rockville, MD 20850
Phone: (301) 977-3654
E-mail: p.tunon@expressionpathology.com

   
Record changed: 2016-03-19

Advertisement

Picture [iito] No Tracking 650x80px

More documents for OncoPlex Diagnostics (OncoPlexDx)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81




» top